KLRA
+$0
4.15M sh
Koppel Adam
Director, 10% Owner · SEC CIK 1578965
Insider at
KLRA Kailera Therapeutics, Inc.
FHTX Foghorn Therapeutics Inc.
CERE Cerevel Therapeutics Holdings, Inc.
SLDB Solid Biosciences Inc.
APTX Aptinyx Inc.
DRNA Dicerna Pharmaceuticals Inc
SWTX SpringWorks Therapeutics, Inc.
RPID RAPID MICRO BIOSYSTEMS, INC.
BLSA BCLS Acquisition Corp.
ANNX Annexon, Inc.
ARQT Arcutis Biotherapeutics, Inc.
Advertisement
Buy track record
How this insider's open-market purchases have performed0%
of buys now in profit
0 up · 4 down
Avg return since buy−48.3%
Median return−48.5%
Best trade−4.9%
Worst trade−91.3%
Buys scored4 (+4 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+5.4%
50% won · 4 trades
After 3 months
+7.8%
67% won · 3 trades
After 6 months
−13.6%
33% won · 3 trades
After 12 months
−6.9%
67% won · 3 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | KLRA | $16 | $25M | +7.4% | −18.4% | — | — | — | −23.2% | |
| Jul 19, 2021 | RPID | $20 | $2M | +1.2% | −2.8% | −8.9% | −63.3% | −78.3% | −91.3% | |
| Jul 28, 2020 | ANNX | $17 | $6.8M | +14% | +34.9% | +32.2% | +25.0% | +21.5% | −73.8% | |
| Feb 4, 2020 | ARQT | $17 | $5M | +8.0% | +8.1% | +0.1% | −2.6% | +36.1% | −4.9% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 4 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$277.22M
8 trades
Open-market sells
$197.33M
3 trades
Net flow
+$79.9M
Net buying
Total filings
26
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstKLRA
Koppel Adam, KLRA's 10% owner, spent $25M of their own money on 1.56M shares at $16, growing their stake 7%.
+$25M
1.56M sh @ $16
CERE
−$0
65.68M sh
CERE
+$0
10,461 sh
SLDB
+$5M
904,160 sh @ $6
Advertisement
CERE
Koppel Adam, CERE's 10% owner, spent $125M of their own money on 5.48M shares at $23, growing their stake 9%.
+$125M
5.48M sh @ $23
CERE
−$0
432,627 sh
DRNA
−$127.5K
3,333 sh @ $38
DRNA
−$117.82M
3.08M sh @ $38
SWTX
Bain Capital Life Sciences Investors, Llc sold $70.25M of SWTX, trimming their stake 17%.
−$70.25M
1M sh @ $70
RPID
+$0
1.33M sh
RPID
Bain Capital Life Sciences Investors, Llc, RPID's 10% owner, spent $2M of their own money on 100,000 shares at $20, growing their stake 1%.
+$2M
100,000 sh @ $20
DRNA
+$0
3,333 sh
SLDB
+$5M
869,565 sh @ $6
SWTX
Bain Capital Life Sciences Investors, Llc sold $103.68M of SWTX, trimming their stake 20%.
−$103.68M
1.45M sh @ $72
DRNA
−$23.4M
1M sh @ $23
SLDB
+$11.8M
3.19M sh @ $4
CERE
Koppel Adam, CERE's 10% owner, spent $3.42M of their own money on 332,293 shares at $10, growing their stake 1%.
+$3.42M
332,293 sh @ $10
CERE
+$0
49.96M sh
CERE
Koppel Adam, CERE's 10% owner, spent $100M of their own money on 10M shares at $10, growing their stake 20%.
+$100M
10M sh @ $10
APTX
Bain Capital Life Sciences Investors, Llc, APTX's 10% owner, spent $10M of their own money on 3.33M shares at $3, growing their stake 60%.
+$10M
3.33M sh @ $3
BLSA
+$4.88M
487,500 sh @ $10
ANNX
+$0
319,243 sh
ANNX
Bain Capital Life Sciences Investors, Llc, ANNX's 10% owner, spent $6.8M of their own money on 400,000 shares at $17, growing their stake 14%.
+$6.8M
400,000 sh @ $17
ARQT
+$0
859,573 sh
ARQT
Bain Capital Life Sciences Investors, Llc, ARQT's 10% owner, spent $5M of their own money on 294,117 shares at $17, growing their stake 8%.
+$5M
294,117 sh @ $17
Frequently asked questions
How is Koppel Adam's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from Koppel Adam's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.